CGS 18102Alternative Names: CGS 18102A
Latest Information Update: 13 Dec 1995
At a glance
- Originator Novartis
- Class Anxiolytics
- Mechanism of Action Serotonin 1A receptor agonists; Serotonin 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 13 Dec 1995 CGS 18102A is now called CGS 18102